Guardant Health (NASDAQ:GH) Price Target Raised to $60.00

Guardant Health (NASDAQ:GH) had its price objective hoisted by Barclays from $55.00 to $60.00 in a research report report published on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock.

GH has been the topic of a number of other research reports. Canaccord Genuity Group raised their price target on Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Mizuho assumed coverage on Guardant Health in a report on Thursday, April 10th. They set an “outperform” rating and a $55.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Stifel Nicolaus lifted their price target on shares of Guardant Health from $53.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Raymond James reaffirmed an “outperform” rating and issued a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Twenty-one equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $51.64.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $46.85 on Thursday. The firm has a fifty day moving average price of $43.74 and a two-hundred day moving average price of $38.23. The company has a market cap of $5.78 billion, a price-to-earnings ratio of -13.16 and a beta of 1.45. Guardant Health has a one year low of $18.01 and a one year high of $52.92.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $203.47 million for the quarter, compared to analysts’ expectations of $189.91 million. During the same period in the prior year, the business earned ($0.46) earnings per share. Guardant Health’s revenue for the quarter was up 20.8% compared to the same quarter last year. Equities research analysts expect that Guardant Health will post -2.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in Guardant Health by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company’s stock worth $368,205,000 after buying an additional 350,606 shares during the last quarter. Deep Track Capital LP boosted its holdings in Guardant Health by 7.0% in the fourth quarter. Deep Track Capital LP now owns 6,419,566 shares of the company’s stock worth $196,118,000 after acquiring an additional 419,006 shares in the last quarter. Two Sigma Advisers LP grew its stake in shares of Guardant Health by 96.7% during the fourth quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock worth $70,742,000 after acquiring an additional 1,138,300 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Guardant Health by 38.5% during the fourth quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company’s stock valued at $57,761,000 after acquiring an additional 525,368 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Guardant Health by 19.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company’s stock valued at $44,732,000 after acquiring an additional 238,037 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.